

Peter H Schafer

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4253518/peter-h-schafer-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28
papers

2,299
citations

21
h-index

30
g-index

30
ext. papers

2,625
ext. citations

4.4
avg, IF

5.08
L-index

#	Paper	IF	Citations
28	Keynote review: phosphodiesterase-4 as a therapeutic target. <i>Drug Discovery Today</i> , 2005 , 10, 1503-19	8.8	530
27	Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). <i>British Journal of Haematology</i> , 2014 , 164, 811-21	4.5	361
26	Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. <i>Biochemical Pharmacology</i> , 2012 , 83, 1583-90	6	273
25	Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 305, 1222-32	4.7	149
24	Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor- α inhibitor. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 1522-4	8.3	121
23	Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010 , 2, 271-8	3.8	106
22	Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor- α from human rheumatoid synovial cells and ameliorates experimental arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R107	5.7	93
21	Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. <i>Leukemia Research</i> , 2006 , 30, 849-58	2.7	89
20	Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF- α , IL-1 β , and LPS-stimulated human PBMC in a partially IL-10-dependent manner. <i>Cellular Immunology</i> , 2004 , 230, 81-8	4.4	67
19	Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. <i>Cellular Signalling</i> , 2016 , 28, 753-63	4.9	62
18	JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. <i>Clinical and Translational Medicine</i> , 2016 , 5, 36	5.7	53
17	Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. <i>Arthritis Research and Therapy</i> , 2015 , 17, 249	5.7	51
16	Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. <i>Journal of Drugs in Dermatology</i> , 2013 , 12, 888-97	2.2	51
15	The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). <i>Journal of Immunology Research</i> , 2015 , 2015, 906349	4.5	49
14	Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity. <i>Journal of Immunology</i> , 2017 , 199, 2388-2407	5.3	34
13	Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2018 , 17, 835-840	2.2	31
12	Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1663-72	3.5	29

11	Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study. <i>Rheumatology and Therapy</i> , 2020 , 7, 101-119	4.4	29
10	Apremilast Ameliorates Experimental Arthritis Suppression of Th1 and Th17 Cells and Enhancement of CD4Foxp3 Regulatory T Cells Differentiation. <i>Frontiers in Immunology</i> , 2018 , 9, 1662	8.4	25
9	Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4. <i>Journal of the American Academy of Dermatology</i> , 2013 , 68, 1041-2	4.5	24
8	Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2013 , 8, e80437	3.7	24
7	Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 1010-1013.e6	11.5	20
6	IL-12/IL-23p40 identified as a downstream target of apremilast in models of arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019 , 11, 1759720X19828669	3.8	9
5	Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice. <i>Drugs in R and D</i> , 2019 , 19, 329-338	3.4	9
4	Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects. <i>Scientific Reports</i> , 2020 , 10, 605	4.9	6
3	Apremilast mechanism of efficacy in systemic-naïve patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. <i>Journal of Dermatological Science</i> , 2019 , 96, 126-133	4.3	4
2	Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial. <i>Journal of Dermatology</i> , 2021 , 48, 80-84	1.6	0
1	Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1541-2	4	